GUARDANT HEALTH INC

Guardant Health’s liquid‑biopsy tech, Guardant360, is reshaping cancer diagnostics—non‑invasive, real‑time tumor monitoring that could change patient care worldwide.

Explore Guardant Health’s growth story: market cap $20.7B, cutting‑edge liquid biopsy tech, FDA momentum, and partnership gains driving future upside.

Guardant Health’s directors buy ~4k shares each, boosting holdings while the biotech firm remains a key player in cancer diagnostics – see the latest share‑ownership updates.

Guardant Health insider sales spark debate: are executives selling shares amid a shaky P/E and fierce competition, or is it routine portfolio management?

Guardant Health’s insider sales and Evercore’s lowered price target signal changing investor confidence; explore how these SEC filings and market shifts affect the biotech stock’s future.

Guardant Health insider sale sparks volatility concerns: negative P/E, shaky growth, and strategic recalibration needed for investors to assess sustainability.

Guardant Health expands its liquid‑biopsy Reveal test to monitor late‑stage cancer therapy and launches a global consortium to standardize exabyte‑scale data for AI‑driven oncology research.

Guardant Health raises $650 M with upsized convertible notes and a public equity deal, fueling precision‑oncology expansion while sparking concerns over debt and dilution.

Guardant Health reports a 39 % Q3 revenue jump, raises FY 2025 outlook to $965‑$970 M, and sees a 26 % pre‑market lift as investors back its precision oncology growth.

Guardant Health Inc. reports a 31% increase in revenue for Q2 2025, exceeding analyst estimates and positioning the biotechnology company for continued success in the rapidly evolving field of cancer diagnostics.